Active ingredients of dual-action Combivent® (ipratropium bromide and albuterol sulfate) Inhalation Aerosol now delivered by new propellant-free inhaler RIDGEFIELD, Conn., Oct. 10, 2011 /PRNewswire/ - ...

Inhalation: The recommended dose (ipratropium bromide nasal spray 0.03%) is two sprays (42 mcg) per nostril two or three times daily (total dose 168 to 252 mcg/day).

RIDGEFIELD, Conn., April 13 /PRNewswire/ -- Boehringer Ingelheim Pharmaceuticals, Inc. (BIPI) today announced that the U.S. Food and Drug Administration (FDA) has determined that the "essential use" ...

Learn everything you need to know about Ipratropium Bromide-pronunciation, uses, dosage guidelines, indications, and when to take or avoid it. Get up-to-date information on side effects, precautions, ...

The FDA has advised consumers not to use albuterol sulfate inhalation solution, 0.083%, and ipratropium bromide inhalation solutions, 0.02%, unit-dose vials, purchased after September 8, 2009 and ...

RANCHO CUCAMONGA, CA / ACCESS Newswire / February 24, 2026 / Amphastar Pharmaceuticals, Inc. (NASDAQ:AMPH) announced that the U.S. Food and Drug Administration ("FDA") has approved the Company's ...

Background: Studies have suggested an increased risk of cardiovascular morbidity and mortality associated with the use of ipratropium bromide. We sought to examine the association between ipratropium ...

(HealthDay)—There are no significant clinical differences between the use of a breath-actuated nebulizer (BAN) and a handheld nebulizer (HHN) for the treatment of wheezing or dyspnea among adults seen ...

We used national Veteran's Health Administration health-care databases for this analysis, including inpatient and outpatient data, pharmacy data, and vital status information. The cohort in this ...

RANCHO CUCAMONGA, CA / ACCESS Newswire / February 24, 2026 / Amphastar Pharmaceuticals, Inc. (NASDAQ:AMPH) announced that the U.S. Food and Drug Administration ("FDA") has approved the Company's ...